Table 4.
Drug thresholds used to categorize patients’ outcomes in observational studies
| Study | Drug | Threshold (μg/mL) | Outcome |
|---|---|---|---|
| Ben-Bassat O [35] | IFX | 2 | Remission |
| Drastich P [45] | IFX | 2 | Remission |
| Murthy S [46] | IFX | 2 | Remission |
| Maser EA [47] | IFX | 1.4 | Remission |
| Reinisch W [48] | IFX | 3 | Remission |
| Seow CH [49] | IFX | 2 | Remission |
| Steenholdt C [50] | IFX | 0.5 | Remission |
| Vande Casteele [16] | IFX | 2.2 | CRP |
| Feagan BG [51] | IFX | 3 | CRP |
| Bortlik M [52] | IFX | 3 | CRP |
| Mazor Y [53] | ADA | 5 | Remission |
| Imaeda H [54] | ADA | 10 | CRP |
IFX = infliximab; ADA = adalimumab; CRP = C-reactive protein